Gilteritinib Induces Differentiation in Relapsed and Refractory -mutated Acute Myeloid Leukemia

Overview

Journal Blood Adv

Specialty Hematology

Date 2019 May 25

PMID 31122910

Citations 36

Authors

Christine M McMahon

Jonathan Canaani

Bryan Rea

Rachel L Sargent

Julianne N Qualtieri

Christopher D Watt

Jennifer J D Morrissette

Martin Carroll

Alexander E Perl

Affiliations

Soon will be listed here.

Citing Articles

Acute Myeloid Leukaemia and Acute Lymphoblastic Leukaemia Classification and Metabolic Characteristics for Informing and Advancing Treatment.

Wemyss C, Jones E, Stentz R, Carding S Cancers (Basel). 2025; 16(24.

PMID: 39766036 PMC: 11675077. DOI: 10.3390/cancers16244136.

Cholesterol inhibition enhances antitumor response of gilteritinib in lung cancer cells.

Sun C, Cao D, Wang Y, Weng N, Ren Q, Wang S Cell Death Dis. 2024; 15(9):704.

PMID: 39349433 PMC: 11443066. DOI: 10.1038/s41419-024-07082-x.

Monocytic Differentiation in Acute Myeloid Leukemia Cells: Diagnostic Criteria, Biological Heterogeneity, Mitochondrial Metabolism, Resistance to and Induction by Targeted Therapies.

Bruserud O, Selheim F, Hernandez-Valladares M, Reikvam H Int J Mol Sci. 2024; 25(12).

PMID: 38928061 PMC: 11203697. DOI: 10.3390/ijms25126356.

Inhibition of Enhancer of Zeste Homolog 2 Induces Blast Differentiation, Impairs Engraftment and Prolongs Survival in Murine Models of Acute Myeloid Leukemia.

Fobare S, Elgamal O, Wunderlich M, Stahl E, Mehmood A, Furby C Cancers (Basel). 2024; 16(3).

PMID: 38339323 PMC: 10854504. DOI: 10.3390/cancers16030569.

FLT3 tyrosine kinase inhibition modulates PRC2 and promotes differentiation in acute myeloid leukemia.

Sung P, Selvam M, Riedel S, Xie H, Bryant K, Manning B Leukemia. 2024; 38(2):291-301.

PMID: 38182819 PMC: 11141246. DOI: 10.1038/s41375-023-02131-4.

References

Perl A, Altman J, Cortes J, Smith C, Litzow M, Baer M . Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Lancet Oncol. 2017; 18(8):1061-1075. PMC: 5572576. DOI: 10.1016/S1470-2045(17)30416-3. View

Galanis A, Levis M . Inhibition of c-Kit by tyrosine kinase inhibitors. Haematologica. 2014; 100(3):e77-9. PMC: 4349281. DOI: 10.3324/haematol.2014.117028. View

Lee L, Hernandez D, Rajkhowa T, Smith S, Raman J, Nguyen B . Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor. Blood. 2016; 129(2):257-260. PMC: 5234222. DOI: 10.1182/blood-2016-10-745133. View

Sexauer A, Perl A, Yang X, Borowitz M, Gocke C, Rajkhowa T . Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML. Blood. 2012; 120(20):4205-14. PMC: 3501718. DOI: 10.1182/blood-2012-01-402545. View

Cheson B, Bennett J, Kopecky K, Buchner T, Willman C, Estey E . Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003; 21(24):4642-9. DOI: 10.1200/JCO.2003.04.036. View

Varadarajan N, Boni A, Elder D, Bagg A, Micheletti R, Perl A . FLT3 Inhibitor-Associated Neutrophilic Dermatoses. JAMA Dermatol. 2016; 152(4):480-2. DOI: 10.1001/jamadermatol.2015.6121. View

Amatangelo M, Quek L, Shih A, Stein E, Roshal M, David M . Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. Blood. 2017; 130(6):732-741. PMC: 5553578. DOI: 10.1182/blood-2017-04-779447. View

Fathi A, Le L, Hasserjian R, Sadrzadeh H, Levis M, Chen Y . FLT3 inhibitor-induced neutrophilic dermatosis. Blood. 2013; 122(2):239-42. DOI: 10.1182/blood-2013-01-478172. View

Cortes J, Perl A, Dohner H, Kantarjian H, Martinelli G, Kovacsovics T . Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2018; 19(7):889-903. PMC: 8152787. DOI: 10.1016/S1470-2045(18)30240-7. View

10.

Cortes J, Tallman M, Schiller G, Trone D, Gammon G, Goldberg S . Phase 2b study of 2 dosing regimens of quizartinib monotherapy in -ITD-mutated, relapsed or refractory AML. Blood. 2018; 132(6):598-607. PMC: 6085992. DOI: 10.1182/blood-2018-01-821629. View

11.

Smith C, Wang Q, Chin C, Salerno S, Damon L, Levis M . Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature. 2012; 485(7397):260-3. PMC: 3390926. DOI: 10.1038/nature11016. View

12.

Nybakken G, Canaani J, Roy D, Morrissette J, Watt C, Shah N . Quizartinib elicits differential responses that correlate with karyotype and genotype of the leukemic clone. Leukemia. 2015; 30(6):1422-5. PMC: 4927337. DOI: 10.1038/leu.2015.320. View

13.

Stein E, DiNardo C, Pollyea D, Fathi A, Roboz G, Altman J . Enasidenib in mutant relapsed or refractory acute myeloid leukemia. Blood. 2017; 130(6):722-731. PMC: 5572791. DOI: 10.1182/blood-2017-04-779405. View

14.

DiNardo C, Stein E, de Botton S, Roboz G, Altman J, Mims A . Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. N Engl J Med. 2018; 378(25):2386-2398. DOI: 10.1056/NEJMoa1716984. View

15.

Levis M, Perl A, Altman J, Gocke C, Bahceci E, Hill J . A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with -ITD mutations. Blood Adv. 2018; 2(8):825-831. PMC: 5916006. DOI: 10.1182/bloodadvances.2018015925. View